Centre Hospitalier Lyon Sud
- Address
- lock Available on a paid plan
Centre Hospitalier Lyon Sud - Advanced Oncology & Hematology Research
Centre Hospitalier Lyon Sud is a premier clinical research institution conducting innovative studies across multiple cancer types and blood disorders. The center demonstrates particular expertise in precision oncology and targeted therapy approaches, with a strong focus on developing personalized treatment strategies for patients with advanced malignancies.
- Multiple Myeloma: Novel immunotherapy combinations including elranatamab monotherapy and combination regimens for relapsed/refractory disease
- Advanced Lung Cancer: Targeted therapies for NSCLC with EGFR mutations, ALK rearrangements, and ROS1 fusion following progression on targeted therapies
- Hematologic Malignancies: Innovative approaches in polycythemia vera, chronic lymphocytic leukemia, and haploidentical hematopoietic stem cell transplantation
- Gastrointestinal & Gynecologic Cancers: Advanced studies in colorectal cancer with BRAF mutations, metastatic gastric cancer, and ovarian cancer utilizing hyperthermic intraperitoneal chemotherapy
The center's research portfolio encompasses both Phase II and Phase III clinical trials, demonstrating comprehensive capabilities from early efficacy assessments to large-scale comparative effectiveness studies. The institution shows particular strength in evaluating novel immunotherapy combinations, molecular targeted agents, and surgical innovations for head and neck malignancies including salivary gland and sinus tumors, positioning it at the forefront of oncological care and research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Lyon Sud
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy, Immunogenicity, and Safety of OVX836 Influenza Vaccine in Preventing RT-PCR-Confirmed Influenza Type A in Healthy Adults Aged 18-59: A Phase 2b Study | Osivax | Phase II | Not Recruiting | Sep 2025 | May 2026 |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 3 | Unknown | 2011-04-26 | 2019-08-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.